Table 1.
Baseline characteristics patients treated on this trial (N = 24)
| Demographics | ||
| Median age (years, IQR) | 63.8 | (56.7–72.4) |
| Race, n (%) | 19 | (79) |
| Caucasian | ||
| Gender, n (%) | ||
| Male | 18 | (75) |
| Female | 6 | (25) |
| Location of primary tumor, n (%) | ||
| Bladder | 16 | (67) |
| Renal pelvis | 9 | (38) |
| Ureter | 7 | (29) |
| Urethra | 1 | (4) |
| Hemoglobin (g/dl) (median, IQR) | 11.3 | (10.6–12.3) |
| Location of metastasisa, n (%) | ||
| Nodal/soft tissue | 16 | (67) |
| Lung/pleura | 9 | (38) |
| Liver | 9 | (38) |
| Bone | 6 | (25) |
| Other sites | 4 | (17) |
| Nodal versus other metastasis, n (%) | ||
| Nodal metastases only | 7 | (29) |
| Nonnodal metastases | 17 | (71) |
| Prior chemotherapy, n (%) | ||
| Gemcitabine/cisplatin | 13 | (54) |
| Gemcitabine/cisplatin/paclitaxel | 1 | (4) |
| Gemcitabine/cisplatin/gefitinib | 1 | (4) |
| Gemcitabine/carboplatin | 6 | (25) |
| Gemcitabine/carboplatin/paclitaxel | 3 | (13) |
a
May add up to >100% due to multiple organ sites of disease.
IQR, interquartile range.